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Beyond the FDA PRO Guidance: Steps toward Integrating Meaningful
Patient-Reported Outcomes into Regulatory Trials and US Drug Labels1
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OWhen sitting with a patient—or as a patient—deciding whether to
start a treatment, often the first question asked is, “how will it
make me feel” or “how have others like me felt.” Yet this informa-
tion is conspicuously absent from most US drug labels and pub-
lished results of regulatory clinical trials.
The guiding principle here is that the patient perspective,
which is usually best captured via a patient-reported outcome
(PRO) measure, is always relevant and should be assessed in all
pivotal clinical trials unless the impact of a product on the patient
experience is already well known. Even if a product is expected to
have little or no impact on how a patient feels, substantiating that
expectation with data is informative to decision makers. Patient-
reported information may reflect symptomatic benefits or symp-
tomatic toxicities of a product or may demonstrate impact on the
overall patient experience measured as health-related quality of
life (HRQOL). Arguably, not including such information in a trial or
label represents an omission that results in decision makers hav-
ing incomplete information to balance risks with benefits.
Why is this information so often missing from labels? Is it that
sponsors simply do not measure patients’ symptoms or HRQOL?
Or perhaps sponsors do collect this information but the Food and
Drug Administration (FDA) feels their approaches are method-
ologically inadequate to merit inclusion in labels? Or maybe it is
overly challenging or infeasible to collect and analyze patient re-
ports compared with survival-based or surrogate end points.
An informative new article in the current issue of Value in Health
[1] provides descriptive data suggesting that all the above reasons
may contribute, but, as described below, are surmountable.
Current status: The sponsor
While industry sponsors do include PRO measures in many stud-
ies, these are often generic tools used to enable economic analyses
by European regulators or to explore HRQOL and nonspecific
symptoms. Outcomes and measures are frequently selected late
in a development cycle when it is too late to conduct qualitative
work to establish which outcomes are most important in the tar-
get population, or to assess how measures perform. Statistical
power is rarely reserved for PRO analyses in pivotal trials. A dis-
connect between clinical investigators and PRO experts lies within
most companies; this limits the possibility that PROs will be prom-
inent in a study design. PRO experts tend to be associated more
closely with postmarketing research units than with preapproval
clinical development teams, and therefore PROs are more fre-
quently integrated into observational research following approval
to help guide marketing strategy. But this information often is not
published or is unavailable to regulators, patients, clinicians, orSource of financial support: The authors have no other financial relpayers. Moreover, after a product is approved or labeled, it is gen-
erally too late to conduct informative comparative research.
Current status: The FDA
The FDA plays a gatekeeper role to ensure that poor quality infor-
mation is not used as the basis of approval or labeling. Historically,
many patient questionnaires were not well developed and gener-
ated untrustworthy data. The FDA produced a PRO Guidance (draft
2006; final 2009) that was a major advancement toward establish-
ing methodological standards for developing and using PRO mea-
sures [2]. But the science of PRO measurement and the community
of experts in this field have advanced substantially over the past
decade. There have been critiques from some members of this
community that overly stringent application of Guidance princi-
ples by the FDA has hindered rather than promoted inclusion of
PROs in labels. The article by DeMuro et al. [1] in this issue of Value
in Health reports that 25% of labels since 2006 include PRO end
points. It is debatable whether this represents a triumph or failure
of the Guidance or of the movement toward making drug labels
more patient-centered. It can be spun either way, although the
article’s authors suggest that 25% is a small number given the 50%
of drug approval packages that include PRO end points. But the
more salient questions here are whether the FDA is appropriately
critiquing current uses of PROs, whether it is feasible for sponsors
to meet FDA standards in most cases, and whether the right PROs
are being integrated into the right studies. The article substanti-
ates what many sponsors and the FDA have anecdotally pointed
out: that there is still quite a bit of heterogeneity in how PRO end
points are designed by sponsors and in how they are considered
across and within FDA review divisions.
Moving forward: The sponsor role
So where are we to go from here? Below (and summarized in Table
) is a proposed path forward for sponsors:
Every drug development program should consider early on how
nformation elicited from patients could be informative to deci-
ion makers who will ultimately use, prescribe, or pay for a prod-
ct. This includes assessment of symptoms that may be alleviated
y a product, symptomatic side effects, and changes in overall
RQOL or health state. An underlying fundamental change in cul-
ure is necessary, in which the value and feasibility of including
ROs is understood by clinical investigators and leadership.
perationalization involves the following:ationships to disclose.
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ulation is identified, work should begin to see what symptoms
are important in patients representing that population (unless
already well known). A small number of one-on-one inter-
views, focus groups, or multisymptom screening surveys in
untreated patients plus a literature review can quickly identify
whether there are specific symptoms or functional impair-
ments of importance. Early information can be gathered to ex-
plore whether the treatment alleviates any of the baseline
symptoms and whether there are symptomatic toxicities asso-
ciated with the treatment. These become the PROs of interest.
● Next, measures must be identified or developed to assess these
PROs. Again, the earlier the better in a program. This is where
the FDA Guidance has raised the bar a bit, but it is not insur-
mountable by any means. The most important step is to ensure
that measures being used are considered meaningful in the
target population, which can be done through interviews in a
small number of patients [3]. Translations should be consid-
ered early if an ultimate multinational study is foreseen, and a
number of companies specialize in translating PRO tools effi-
ciently and inexpensively in keeping with established stan-
dards [4]. Early engagement of FDA reviewers to ensure that a
plan is consistent with FDA expectations is highly advisable.
● PRO measures can be particularly informative in dose finding
and should be considered for use to ensure that there are not
excessive side effects from the patient perspective—an ele-
ment that is frequently ignored in drug development, leading
to potential selection of inappropriately high doses (which
real-world patients may ultimately not wish to endure).
● PRO measures are useful and should be considered
in phase 3 trials to 1) demonstrate comparative benefits or
comparative tolerability from the patient perspective; 2) en-
hance progression-free survival end points and surrogate end
points to substantiate that a product impacts how a patient
feels or functions; and 3) screen for symptomatic adverse
events from the patient perspective (notably, patients better
detect baseline symptoms than staff, and so when symptoms
are detected during a study it is more clear via PROs whether
they were preexisting) [5]. Again, it is as useful to decision mak-
ers to know that there is no effect on symptoms as to know that
there is, and so PRO data are always informative. PRO end
points should be included as primary or secondary end points
with adequate statistical power reserved for them. Measures to
Table 1 – Recommendations for industry sponsors and for
patient-reported outcome (PRO) end points in pivotal trials
rigor.
Recommendations for sponsors
1. Create ongoing relationships between clinical development
teams and internal or external PRO experts.
2. Evaluate potential value of PROs in every clinical development
program, starting during early-phase research. Consider how
PROs would inform decision makers including patients,
clinicians, regulators, and payers.
3. Engage FDA early to discuss the role of PRO end points and
specific measurement strategies.
4. Conduct early qualitative research to identify outcomes
important to patients including symptoms of disease,
symptomatic toxicities of a product, and impact of the product
on global health-related quality of life.
5. Include PROs as primary or secondary end points in pivotal trials,
with adequate statistical power. Provide a rationale if PROs are
not included as an endpoint (such as if the impact of the product
on the patient experience is already known).
FDA, Food and Drug Administration; SEALD, Study End points and Laminimize missing data, such as backup data collection meth-ods and reminders to patients, should be employed, as well as
an a priori plan for imputing missing PRO data.
Moving forward: The FDA role
Below (and summarized in Table 1) is a proposed path forward for
the FDA:
FDA reviewers should consider the potential role of PROs to
support understanding of the properties of every product and
should consider a sponsor’s research plan to be incomplete if the
direct patient perspective is not represented (or if a justification
for not collecting the patient perspective is not included). Opera-
tionalization involves the following:
● The FDA needs more expertise on PRO measurement. Wide-
spread interest in a more patient-centered regulatory process
and the heterogeneity in approaches identified in the new ar-
ticle in this issue ofValue in Health indicates that this is an acute
need. To get there necessitates a three-pronged approach: 1)
reviewers must become better versed in the methods of PRO
measurement; 2) statisticians with expertise in analyzing PRO
data must be developed, hired, or contracted; and 3) the staff of
the FDA’s internal PRO resource, Study Endpoints and Labeling
(SEALD), must be expanded with well-qualified and thoughtful
individuals who communicate effectively with the review divi-
sions and who have sufficient experience in PRO measure de-
velopment and clinical research to be realistic about the bal-
ance between the rigor and feasibility of implementing PRO
end points. At least six hires of mid-level professional staff or
contractors into SEALD with associated administrators is nec-
essary to address existing needs. Recent FDA requests to use
congressional allocations to support PRO expertise could be
directed in these three areas.
● FDA reviewers should engage sponsors early to emphasize the
importance of including PROs in development research when
the impact of a product on the patient experience is not already
known (or require a justification for why it is not included).
Applications and proposed drug labels without information
about the patient subjective experience should be considered
incomplete. Abundant research demonstrates that no other
source of information can substitute for patient direct reports,
and information about symptoms from other sources such as
DA to consider toward increasing success including
US drug labels, without compromising methodological
Recommendations for the FDA
1. Increase internal FDA PRO measurement expertise, both within
review divisions and by expanding SEALD.
2. Consider PROs as essential information to understand the
properties of a product, without which a submission is
incomplete.
3. Encourage sponsors to incorporate and develop PRO measures
early in a product development program.
4. Relax stringency around accepting health-related quality-of-life
data for inclusion in labels.
5. Adjust criteria for concluding an established PRO measure is fit
for purpose in a new target population or context, to require only
limited qualitative but not further quantitative evidence.
g.the F
andclinicians substantially underestimates prevalence and sever-
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acceptable to FDA for collecting this information.
The FDA should consider relaxing its stringency about generic
or HRQOL tools. These should be viewed as acceptable for la-
beling purposes if demonstrated to have robust measurement
properties. An outdated argument against such measures has
been that it is unclear what exactly they are measuring and
that they represent a composite of experiences including
symptomatic improvement, toxicity, functional status, or psy-
chosocial status. But what is more important than quality of
life? Arguably, most other regulatory end points also represent
multifactor common final pathways (including overall sur-
vival). Single items asking patients about their quality of life
perform well from a methodological standpoint and are highly
correlated with meaningful outcomes such as symptoms, per-
formance status, disease regression/progression, and survival.
There is a compelling case for these end points to be accepted
as a basis for labeling (or as supportive of specific symptom end
points) as they are the most meaningful and important to pa-
tients in many cases. Moreover, generic measures are useful in
economic and comparative effectiveness analyses, which are
standard in Europe and increasingly important in the United
States.
The FDA should consider adjusting its criteria for fitness for
purpose of PRO measures. It could be regarded as sufficient in
most cases for a sponsor to use an existing measure with dem-
onstrated good measurement properties in another popula-
tion, with qualitative research in the new target population
showing that items are meaningful and understood. This could
be an acceptable criterion for concluding fitness for purpose.
Requiring new validation or establishment of clinically mean-
ingful score changes is probably not necessary in more than a
couple of different populations.
Needed regulatory science methods research in
PROs
There are several known methodological knowledge gaps that
present barriers to PRO end points being accepted for inclusion in
US labels, as underlined by the article in this issue of Value in
Health. Improving methods and knowledge in these areas will al-
low sponsors and regulators to feel more comfortable about the
fidelity of PRO analyses:
● Use of PROs in open-label studies or in studies with inadvertent
unbinding of treatment allocation: It is theorized that patient
self-reports are biased when patients believe they are receiving
an active or superior treatment (e.g., a patient realizes he or she
is on the experimental arm of a study, and this leads him or her
to report greater pain improvement). Published literature re-
ports variable effects of such bias on patient reporting, but this
concept serves as an underlying basis for blinding in trials. In
general, the FDA will not accept PRO endpoint data from
trials that are open-label or that are difficult to blind because
of typical or observable side effects associated with one of
the treatments (e.g., rash with tyrosine kinase inhibitors).
The magnitude of this potential bias is not known. It has
been suggested that a sufficiently large effect size require-
ment could overcome this source of bias, if it exists. Research
in this area is warranted to inform study design and review.
● Approach to missing PRO data: Rates of missing data are highly
variable between trials. Research is needed to identify effective
approaches to minimizing missing data including backup data
collection techniques. In addition, standard approaches for im-
puting missing patient-reported data are needed.● Approach to PRO data in multinational or multicultural trials:
Patient responses to PRO questionnaires can vary on the basis
of cultural differences in perceptions of the domains of inter-
est. For example, beliefs about pain and pain management may
differ between cultures. This does not negate the value of using
a measure in a trial spanning cultures, but it may be important
to have a balanced number of patients between arms in major
subcultures. Research on how to accommodate for these dif-
ferences in study results would improve confidence in using
PRO end points in large multinational trials.
Over the past 10 to 15 years, there has been substantial progress in
the methodological science and technical feasibility of collecting
data directly from patients. An increasing general interest in pa-
tient-centeredness, and recognition that the patient perspective is
currently underrepresented in pivotal trials and in US drug labels,
suggests a need for a change in orientation and operationalization
by both industry sponsors and FDA reviewers. The FDA’s PRO
Guidance was a major step forward, and there is now evidence
that almost 25% of US drug labels include PRO end points. But
much progress remains. PRO end points are clearly appropriate
in many more than these labels, and even in the existing labels
with PRO end points, the picture of the patient experience is not
comprehensive in many cases. Systematic processes both in
companies and in the FDA to assess early on what outcomes are
important to patients, and how they should be measured,
should become de rigeur. Until then, we will be left with an
incomplete picture of how products impact end users, and pa-
tients will remain unclear on how “patients like them” felt when
using products.
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